Obesity, kidney dysfunction and hypertension: mechanistic links

JE Hall, JM do Carmo, AA da Silva, Z Wang… - Nature reviews …, 2019 - nature.com
Excessive adiposity raises blood pressure and accounts for 65–75% of primary
hypertension, which is a major driver of cardiovascular and kidney diseases. In obesity …

Treatment of resistant and refractory hypertension

MC Acelajado, ZH Hughes, S Oparil… - Circulation …, 2019 - Am Heart Assoc
Resistant hypertension (RHTN) is defined as uncontrolled blood pressure despite the use
of≥ 3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like …

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double …

R Agarwal, P Rossignol, A Romero, D Garza, MR Mayo… - The Lancet, 2019 - thelancet.com
Background Spironolactone is effective at reducing blood pressure in patients with
uncontrolled resistant hypertension. However, the use of spironolactone in patients with …

Prevalence of apparent treatment-resistant hypertension in the United States: comparison of the 2008 and 2018 American Heart Association scientific statements on …

RM Carey, S Sakhuja, DA Calhoun, PK Whelton… - …, 2019 - Am Heart Assoc
In 2018, the American Heart Association published a Scientific Statement on resistant
hypertension. We compared the prevalence of apparent treatment-resistant hypertension …

[HTML][HTML] Redefining diuretics use in hypertension: why select a thiazide-like diuretic?

M Burnier, G Bakris, B Williams - Journal of hypertension, 2019 - journals.lww.com
Diuretics are listed in hypertension guidelines as one of three equally weighted first-line
treatment options. In order to differentiate between antihypertensives, a lot of discussion has …

Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology

S Bianchi, F Aucella, L De Nicola, S Genovesi… - Journal of …, 2019 - Springer
Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with
kidney disease, particularly in those in whom diabetes and heart failure are present or are …

Resistant hypertension: novel insights

G Lamirault, M Artifoni, M Daniel… - Current hypertension …, 2019 - hal.science
Hypertension is the most common chronic disease and the leading risk factor for disability
and premature deaths in the world, accounting for more than 9 million deaths annually …

[HTML][HTML] 2019 Chinese guideline for the management of hypertension in the elderly

Q Hua, L Fan, J Li - Journal of geriatric cardiology: JGC, 2019 - ncbi.nlm.nih.gov
2019 Chinese guideline for the management of hypertension in the elderly - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

Clinical, biochemical, and genetic characteristics of “nonclassic” apparent mineralocorticoid excess syndrome

A Tapia-Castillo, R Baudrand, A Vaidya… - The Journal of …, 2019 - academic.oup.com
Context Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder,
caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11 β-HSD2) …

Eplerenone versus spironolactone in resistant hypertension: an efficacy and/or cost or just a men's issue?

AA Manolis, TA Manolis, H Melita… - Current hypertension …, 2019 - Springer
Abstract Purpose of Review To review comparative efficacy and tolerability data between the
two main mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone, in …